Last reviewed 2026-05-22 · How we verify

WST01 strain product

Shanghai Jiao Tong University School of Medicine · Phase 2 active Small molecule ✓ Verified May 2026 Quality 0/100

WST01 strain product is a Small molecule drug developed by Shanghai Jiao Tong University School of Medicine. It is currently in Phase 2 development.

The WST01 strain product is a small molecule intervention being studied in a randomized, double-blind, placebo-controlled clinical trial for its potential effects on overweight or obese patients with type 2 diabetes. This product is being investigated as a treatment for conditions related to obesity and type 2 diabetes, including those conditions studied in the clinical trial NCT04797442.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	WST01 strain product
Sponsor	Shanghai Jiao Tong University School of Medicine
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effect of Akkermansia Muciniphila WST01 Strain in Overweight or Obese Patients With Type 2 Diabetes (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

WST01 strain product CI brief — competitive landscape report
WST01 strain product updates RSS · CI watch RSS
Shanghai Jiao Tong University School of Medicine portfolio CI

Frequently asked questions about WST01 strain product

What is WST01 strain product?

WST01 strain product is a Small molecule drug developed by Shanghai Jiao Tong University School of Medicine.

Who makes WST01 strain product?

WST01 strain product is developed by Shanghai Jiao Tong University School of Medicine (see full Shanghai Jiao Tong University School of Medicine pipeline at /company/shanghai-jiao-tong-university-school-of-medicine).

What development phase is WST01 strain product in?

WST01 strain product is in Phase 2.

Manufacturer: Shanghai Jiao Tong University School of Medicine — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing